Matches in SemOpenAlex for { <https://semopenalex.org/work/W3193668363> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W3193668363 abstract "Abstract Purpose Various immunosuppressive factors that inhibit the immune response to cancer are present in cancer cells and the cancer microenvironment. Co-inhibitory and co-stimulatory receptors are dynamically expressed on T-cells as immunoadjuvant molecules that regulate the state of T-cell activity. In this report we focus on immunoadjuvant molecules such as LAG-3, TIM-3, and OX-40, for which there have been few published reports. We investigated the expression of LAG-3, TIM-3, and OX-40 in tumor-infiltrating lymphocytes (TILs), and clinically verified the significance of that expression in relation to neoadjuvant thermotherapy (NAC). Methods A total of 177 patients with resectable early-stage breast cancer were treated with NAC. Estrogen receptor (ER), progesterone receptor (PgR), human epidermal growth factor receptor 2 (HER2), Ki67, LAG-3, TIM-3 and OX-40 status were assessed by immunohistochemistry. Results There were 47 (26.6%) patients with high LAG-3 expression, 31 (17.5%) patients had high TIM-3 expression, and 32 (18.1%) patients had high OX-40 expression. The group with low-LAG-3 expression was significantly smaller than the group with high expression in triple-negative breast cancer (TNBC) (p = 0.038) and HER2-enriched breast cancer (HER2BC) (p = 0.021), and the total number of pathological complete response (pCR) patients was greater (p < 0.001). In TNBC and HER2BC, the pCR rate was significantly higher in the low-LAG-3 expression group than in the high-LAG-3 expression group (p < 0.001) (p = 0.020). Moreover, on multivariate analysis also showed that low-LAG-3 expression status was an independent factor to predict the favorable prognosis (p = 0.014, HR = 8.124) (p = 0.048, HR = 10.400). Conclusions Our findings suggest that LAG-3 may become a biomarker in highly malignant breast cancers such as TNBC and HER2BC that can predict the therapeutic efficacy of NAC." @default.
- W3193668363 created "2021-08-30" @default.
- W3193668363 creator A5017393726 @default.
- W3193668363 creator A5032802077 @default.
- W3193668363 creator A5032903747 @default.
- W3193668363 creator A5053084872 @default.
- W3193668363 creator A5057856862 @default.
- W3193668363 creator A5065433903 @default.
- W3193668363 creator A5065875132 @default.
- W3193668363 creator A5077160140 @default.
- W3193668363 creator A5084684329 @default.
- W3193668363 creator A5085515140 @default.
- W3193668363 date "2021-08-13" @default.
- W3193668363 modified "2023-09-27" @default.
- W3193668363 title "Clinical Significance of Expression of Immunoadjuvant Molecules (LAG-3, TIM-3, OX-40) in Neoadjuvant Chemotherapy for Breast Cancer" @default.
- W3193668363 doi "https://doi.org/10.21203/rs.3.rs-785791/v1" @default.
- W3193668363 hasPublicationYear "2021" @default.
- W3193668363 type Work @default.
- W3193668363 sameAs 3193668363 @default.
- W3193668363 citedByCount "0" @default.
- W3193668363 crossrefType "posted-content" @default.
- W3193668363 hasAuthorship W3193668363A5017393726 @default.
- W3193668363 hasAuthorship W3193668363A5032802077 @default.
- W3193668363 hasAuthorship W3193668363A5032903747 @default.
- W3193668363 hasAuthorship W3193668363A5053084872 @default.
- W3193668363 hasAuthorship W3193668363A5057856862 @default.
- W3193668363 hasAuthorship W3193668363A5065433903 @default.
- W3193668363 hasAuthorship W3193668363A5065875132 @default.
- W3193668363 hasAuthorship W3193668363A5077160140 @default.
- W3193668363 hasAuthorship W3193668363A5084684329 @default.
- W3193668363 hasAuthorship W3193668363A5085515140 @default.
- W3193668363 hasBestOaLocation W31936683631 @default.
- W3193668363 hasConcept C121608353 @default.
- W3193668363 hasConcept C126322002 @default.
- W3193668363 hasConcept C143998085 @default.
- W3193668363 hasConcept C170493617 @default.
- W3193668363 hasConcept C203014093 @default.
- W3193668363 hasConcept C204232928 @default.
- W3193668363 hasConcept C2780110267 @default.
- W3193668363 hasConcept C2909935589 @default.
- W3193668363 hasConcept C502942594 @default.
- W3193668363 hasConcept C530470458 @default.
- W3193668363 hasConcept C71924100 @default.
- W3193668363 hasConcept C84606932 @default.
- W3193668363 hasConcept C8891405 @default.
- W3193668363 hasConcept C98717036 @default.
- W3193668363 hasConceptScore W3193668363C121608353 @default.
- W3193668363 hasConceptScore W3193668363C126322002 @default.
- W3193668363 hasConceptScore W3193668363C143998085 @default.
- W3193668363 hasConceptScore W3193668363C170493617 @default.
- W3193668363 hasConceptScore W3193668363C203014093 @default.
- W3193668363 hasConceptScore W3193668363C204232928 @default.
- W3193668363 hasConceptScore W3193668363C2780110267 @default.
- W3193668363 hasConceptScore W3193668363C2909935589 @default.
- W3193668363 hasConceptScore W3193668363C502942594 @default.
- W3193668363 hasConceptScore W3193668363C530470458 @default.
- W3193668363 hasConceptScore W3193668363C71924100 @default.
- W3193668363 hasConceptScore W3193668363C84606932 @default.
- W3193668363 hasConceptScore W3193668363C8891405 @default.
- W3193668363 hasConceptScore W3193668363C98717036 @default.
- W3193668363 hasLocation W31936683631 @default.
- W3193668363 hasOpenAccess W3193668363 @default.
- W3193668363 hasPrimaryLocation W31936683631 @default.
- W3193668363 hasRelatedWork W2047233110 @default.
- W3193668363 hasRelatedWork W2050936961 @default.
- W3193668363 hasRelatedWork W2375815296 @default.
- W3193668363 hasRelatedWork W2516201043 @default.
- W3193668363 hasRelatedWork W2584184160 @default.
- W3193668363 hasRelatedWork W2765336906 @default.
- W3193668363 hasRelatedWork W2953241133 @default.
- W3193668363 hasRelatedWork W3109088106 @default.
- W3193668363 hasRelatedWork W3198519606 @default.
- W3193668363 hasRelatedWork W4205578220 @default.
- W3193668363 isParatext "false" @default.
- W3193668363 isRetracted "false" @default.
- W3193668363 magId "3193668363" @default.
- W3193668363 workType "article" @default.